<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16690">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889614</url>
  </required_header>
  <id_info>
    <org_study_id>RC15_0345</org_study_id>
    <nct_id>NCT02889614</nct_id>
  </id_info>
  <brief_title>Prevalence Assessment and Characterization of Psychological Disorders Associated With Hypobetalipoproteinemia</brief_title>
  <acronym>HYPOPSY</acronym>
  <official_title>Prevalence Assessment and Characterization of Psychological Disorders Associated With Hypobetalipoproteinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Familial hypobetalipoproteinemia (FHBL, OMIM # 1707730) is a genetic disorder heterozygotic
      of LDL-C metabolism. Clinical manifestation range from asymptomatic patients to metabolic
      (fatty liver, diabetes) or psychiatric disorders still unrecognized. HYPOPSY research, aims
      to evaluate prevalence of hypobetalipoproteinemia, and to characterize specific related
      psychiatric disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Familial hypobetalipoproteinemia (FHBL, OMIM # 1707730) is a genetic disorder heterozygotic
      of LDL-C metabolism (Low Density Lipoprotein - Cholesterol) whose incidence is measured from
      1: 500 to 1: 1000. These heterozygous individuals may be asymptomatic or present some
      clinical (fatty liver, diabetes) or psychiatric manifestations still unrecognized. Moreover,
      these individuals have mostly a longevity syndrome and cardiovascular protection. The FHBL
      is often due to mutations of the APOB (APOlipoprotein B), major component of LDL, VLDL (Very
      Low Density Lipoprotein) and chylomicrons, and in some cases, loss-of-function mutations of
      the serine protease PCSK9, endogenous inhibitor of the LDL receptor.

      HYPOPSY research, aims to evaluate, in a population with psychiatric disorders, the
      prevalence of hypobetalipoproteinemia, and to characterize specific related psychiatric
      disorders.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of hypobetalipoproteinemia (LDL-C ≤ 50 mg/dL without hypolipidemic treatment) among psychiatric patients managed in Nantes University Hospital</measure>
    <time_frame>Inclusion.</time_frame>
    <description>Dosage of LDL-C</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Hypobetalipoproteinemia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypobetalipoproteinemia diagnosis (LDL-C ≤ 50 mg/dL without hypolipidemic treatment)</intervention_name>
    <description>LDL-C dosage.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted in mental Disorders Unit in Nantes University Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted in mental Disorders Unit in Nantes University Hospital

        Exclusion Criteria:

          -  Minor patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bertrand CARIOU, Pr</last_name>
    <phone>0033253482710</phone>
    <email>bertrand.cariou@univ-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabrina LEBOUTER, Dr</last_name>
    <email>sabrina.lebouter@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LEBOUTER Sabrina, Dr</last_name>
      <email>sabrina.lebouter@chu-nantes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 30, 2016</lastchanged_date>
  <firstreceived_date>August 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Hypobetalipoproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
